We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Drug Discovery

Drug Discovery

Stay up to date on the topics that matter to you

Trending News

Cell therapy.

Cell Therapy Treatment Effectively Treats Immune-Compromised Children

A selection of diabetes monitoring and treatment neccessities.

Siblings' Rare Genetic Mutation Offers Clues for Type 1 Diabetes Therapy

High magnification micrograph of microglia cells stained with Rio-Hortega's method (silver carbonate). This type is the ramified or resting microglia that appears in normal brain tissue.

Mobilizing Microglia in the Fight Against Alzheimer’s Disease

Immunotherapy After Kidney Cancer Surgery Improves Overall Survival

Cannabinols Show Neuroprotective Properties in Fruit Flies

Antipsychotic Use in Dementia Linked to Elevated Health Risks

News

Vetter Appoints Oliver Albrecht as Managing Director

Role with company commenced on April 1, 2015.

arGEN-X Opens Expansion Cohort in Phase 1b Study of ARGX-111

Objective is to further characterize the safety of ARGX-111 in patients with MET amplified cancers.

Protea Announces Agreement to Acquire vivoPharm

Combined Company to develop and market new services for pharmaceutical R&D.

Bristol-Myers Squibb and uniQure Enter into Strategic Collaboration

Collaboration to develop gene therapies for cardiovascular diseases.

OncoMed and Lilly Enter Clinical Supply Agreement

Agreement to evaluate the combination of Demcizumab and Alimta® (pemetrexed for injection) in lung cancer.

AMRI to Close Holywell, U.K. API Manufacturing Facility

Company plans to cease operations at the site by the end of 2015.

Merck and Pfizer Finalize Agreement to Co-Promote XALKORI®

Co-promotion of XALKORI allows the alliance between Merck KGaA, Darmstadt, Germany, and Pfizer to establish a combined oncology sales organization in key markets for the program.

Neuropsychiatric Drug Candidate Shows Good Safety & Tolerability

Transition Therapeutics announces results from Phase 1 AME & renal clearance clinical studies of neuropsychiatric drug candidate ELND005.

Personalized Melanoma Vaccines Marshal Powerful Immune Response

Vaccines target unique mutations in each patient’s tumor.

Strengthening of Cash Position and Development of ASTrIA Product Platform

Positive results for Col-Treg, second product candidate, in an auto-immune uveitis model.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter